A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
48
Participants
Timeline
Start Date
April 30, 2012
Primary Completion Date
June 30, 2012
Study Completion Date
June 30, 2012
Conditions
Drug-Drug Interaction (DDI)Healthy Subjects
Interventions
DRUG
ASP3652
Oral
DRUG
Gemfibrozil
Oral
DRUG
Repaglinide
Oral
Trial Locations (1)
HA1 3U
PAREXEL Early Phase Clinical Unit, Harrow
All Listed Sponsors
lead
Astellas Pharma Europe B.V.
INDUSTRY
NCT01797198 - A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects | Biotech Hunter | Biotech Hunter